We are live on ! Find out more
IVM

InterWest Venture Management Portfolio holdings

AUM $20.6M
1-Year Est. Return 48.5%
This Fund
S&P 500
This Quarter Est. Return
-22.83%
1 Year Est. Return
+48.5%
3 Year Est. Return
-57.65%
5 Year Est. Return
-76.52%
10 Year Est. Return
–
AUM
$169M
AUM Growth
-$72.3M
Cap. Flow
-$15.5M
Cap. Flow %
-9.14%
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
PMVP icon
PMV Pharmaceuticals
PMVP
+$15.3M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$127K

Sector Composition

Rank Sector Weight
1 Healthcare 67.84%
2 Consumer Discretionary 16.15%
3 Technology 16.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PMVP icon
1
PMV Pharmaceuticals
PMVP
$62.9M
$74.7M 44.17%
3,234,911
-635,000
-16% -$15.3M
REAL icon
2
The RealReal
REAL
$1.4B
$27.3M 16.15%
2,354,080
– –
AI icon
3
C3.ai
AI
$1.37B
$27.1M 16.01%
866,774
– –
SERA icon
4
Sera Prognostics
SERA
$80.3M
$16.6M 9.81%
2,416,241
– –
GKOS icon
5
Glaukos
GKOS
$8.92B
$15.6M 9.2%
350,264
– –
EIGR
6
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.97M 2.35%
25,497
– –
AGTC
7
DELISTED
Applied Genetic Technologies Corporation
AGTC
$2.67M 1.58%
1,404,515
– –
VERO
8
DELISTED
Venus Concept
VERO
$1.12M 0.66%
3,992
– –
DARE icon
9
Dare Bioscience
DARE
$19.8M
$124K 0.07%
5,172
– –
XENE icon
10
Xenon Pharmaceuticals
XENE
$6.36B
– –
-8,293
Closed -$127K

Similar funds

RCP
Rho Capital Partners New York $20.4M AUM
LUGPI
Lightspeed Ultimate General Partner IX Menlo Park, California $20.3M AUM 4.78% 1-Year Est. Return
SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
DOS
David O. Sacks $19.8M AUM 4.02% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
CVSCT
C.V. Starr & Co Trust New York $19.4M AUM 28.57% 1-Year Est. Return
VNB
Virginia National Bank Charlottesville, Virginia $21.9M AUM 12.04% 1-Year Est. Return
BEP
Brookside Equity Partners Stamford, Connecticut $22.5M AUM 62.43% 1-Year Est. Return

InterWest Venture Management's Q4 2021 Portfolio in Review

As of Q4 2021, InterWest Venture Management held 10 positions worth $169M, down 30% from $241M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

InterWest Venture Management withdrew a net $15.5M in Q4 2021, closing 1 position and reducing 1 holding. Its most notable exit was Xenon Pharmaceuticals, an estimated $127K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 71% a quarter earlier, followed by Consumer Discretionary and Technology.

  • InterWest Venture Management's biggest Q4 2021 reduction was PMV Pharmaceuticals, cutting an estimated $15.3M.
  • InterWest Venture Management fully exited Xenon Pharmaceuticals in Q4 2021, selling an estimated $127K.
  • InterWest Venture Management's ten largest holdings make up 100% of its $169M portfolio in Q4 2021.
  • InterWest Venture Management opened 0 new positions and closed 1 in Q4 2021.
  • InterWest Venture Management's portfolio value fell 30% quarter-over-quarter to $169M.

Based on InterWest Venture Management's 13F filing for Q4 2021, filed 25 Jan 2022.